Axovant Is attending the world’s largest and most famous biotechnology international conference iJune 3 - 6 while Benitec is conspicuously absent this year. Is this the reason why our pipeline announcement has been delayed? Axovant own the lion’s share of OPMD and the 6 other pipeline neurological indications. They may have identified the BIO conference as the best time to announce sheep trial data, new indications and OPMD trial preparation progress. Benitec wishing to update the market with news on all programs (proprietary and partnered programs) with the launch of a new website may have been advised to wait for Axovant’s presentation in June.
https://mybio.org/search?utf8=✓&terms=Axovant
Even the Australia’s Biotech Organisation AusBiotech is attending.